LLY vs MASI
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
MASI exhibits a severe valuation disconnect, trading at $178.47 despite a Graham Number of $34.54 and an Intrinsic Value of $26.81. While the Piotroski F-Score of 4/9 indicates stable financial health, the company is struggling with a negative profit margin (-9.92%) and a concerning Q/Q revenue collapse of -31.33%. Strong gross margins and ROE are offset by a significant YoY EPS decline of -31.7% and bearish insider sentiment. The stock is currently priced for perfection in a deteriorating short-term growth environment.
Compare Another Pair
Related Comparisons
LLY vs MASI: Head-to-Head Comparison
This page compares Eli Lilly and Company (LLY) and Masimo Corporation (MASI) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.